The company gins and presses raw cotton into bales and trades various agricultural commodities like cotton seeds, chana, and cattle feed for the Indian domestic market.
The company operates in a highly fragmented, commodity-based industry with razor-thin net margins of 0.7%, indicating a total lack of pricing power. There is no evidence of brand strength or cost advantages, as returns on capital are consistently low and volatile.
Management has prioritized an IPO to fund working capital but has failed to generate meaningful returns on that capital, with EPS collapsing by over 60% despite the fresh equity. Reinvestment is directed toward low-margin trading activities rather than high-return assets.
The business collapsed as the razor-thin 0.7% net margins were entirely consumed by rising interest costs, which the 1.05x coverage ratio could no longer support. The inability of the auditor to verify inventory existence eventually revealed that the reported assets were either non-existent or severely impaired, leading to a total loss of creditworthiness. Management's pivot into unrelated sectors like solar and machinery drained the remaining IPO proceeds into value-destructive projects, while the negative cash conversion cycle forced a liquidity crisis that the promoter's high remuneration only exacerbated.
RichFakir rates Gajanand International Ltd's business quality as poor — 19/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Gajanand International Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Gajanand International Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Gajanand International Ltd's fair value is about ₹2 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →